VMD launches animal medicines safety reporting service

On 10 July 2026, the Veterinary Medicines Directorate launched a new digital service for companies that hold marketing authorisations for animal medicines. That may sound like a niche update for a specialist industry, but it is really a story about how medicine safety is watched after a product is already in use. (gov.uk) The timing matters because this is the second step in a wider rebuild of reporting. The VMD had already opened a separate Adverse Event Reporting Service on 20 May 2026 for animal owners, veterinary professionals and Suitably Qualified Persons, so the regulator is now creating one route for public and clinical reporting and another for the companies responsible for licensed products. (gov.uk)

If you are new to this topic, two bits of jargon are worth translating. A Marketing Authorisation Holder, or MAH, is the company legally responsible for an authorised veterinary medicine, while pharmacovigilance means the ongoing work of spotting, assessing and preventing side effects or other medicine-related problems after approval. (gov.uk) **What this means:** approval is not the finish line. The VMD says medicines are often authorised using trial data from relatively small groups and limited time periods, which is why post-market reporting still matters. The regulator currently monitors more than 6,000 authorised veterinary medicines and receives around 25,000 adverse event reports a year, so better reporting systems are not a nice extra; they are part of how safety oversight works in practice. (gov.uk)

The new VMD Industry Pharmacovigilance Reporting Service pulls several submission types into one place. According to the GOV.UK launch and guidance pages, it can handle Benefit-Risk Submission Reports, Pharmacovigilance Sales Submissions, dose factor justification documents, signal notifications and XML adverse event files. (gov.uk) That consolidation is the useful bit for readers to notice. Instead of treating safety reporting as a trail of separate forms and email chains, the service offers status tracking, exportable logs, in-system validation, digital forms for some report types and a built-in product dictionary to help users identify the right product groups and related information. In plain English, it is meant to make reporting more visible, more checkable and less messy. (gov.uk)

This is where the public-service angle comes in. Good regulation does not only depend on experts making the right final decision; it also depends on people being able to send usable information in the first place. The VMD says it validates reports and then has them assessed by veterinary surgeons, toxicologists and scientists, using both statistical and qualitative methods. (gov.uk) **A quick reality check:** a smarter form cannot do the science for you. What it can do is catch gaps earlier, reduce avoidable admin and give companies a clearer view of what they have submitted. When a regulator is dealing with thousands of products and tens of thousands of reports, those quieter bits of digital design can make the whole safety system work better. This is an inference from the service features and the VMD’s description of how pharmacovigilance data is checked and assessed. (gov.uk)

The new service is also more limited than some readers might first assume. It is for business use only, and the guidance says pet owners and other members of the public should use the separate public-facing reporting service instead. Companies can still keep using the older Veterinary Medicines Digital Service routes for some manual submissions if they prefer, which means this is an expansion of options rather than a hard switch overnight. (gov.uk) That matters because digital change is usually smoother when people are not pushed into it before the system is ready. The VMD is calling this service a beta product, is asking users for feedback inside the system, and says more functions are planned over the next year. In other words, the government is not presenting this as finished; it is presenting it as something to test, improve and build on. (gov.uk)

For a general reader, the biggest lesson here is quite simple. When we talk about medicine safety, we often picture laboratories, inspections or emergency recalls. But a large part of safety work is slower and less visible: someone notices a problem, someone logs it properly, a regulator checks the evidence, and patterns are spotted early enough to act. The VMD says adverse event reporting is vital to monitoring medicines once they are in real-world use. (gov.uk) So yes, this is a niche policy story about veterinary medicines. It is also a small but useful example of what digital public services are for. If reporting is easier for the public, simpler for companies and clearer for regulators, you stand a better chance of protecting animal health, public health and trust in the system at the same time. Businesses that need the new service must register through the official GOV.UK guidance before they can sign in. (gov.uk)